Connect your AI

Avalo Therapeutics AVTX AVTX-009 — Collaborative agreement, milestone payment

Similar metrics at other companies

INCYMilestone and contract revenues — Total revenues

$17M—

DNLIATV:Abeta Program License — Collaborative revenue, revenue from contract with customer

$0—

DNLIMilestone Payment — Total collaboration revenue

$2.5M0.0%

NVAXAdjuvant Products Thereafter — Development, tech transfer, launch, and sales milestone payments

$210M—

ZYMEMilestone revenue — Research and development collaborations

$0-100%

CLYMSales Milestones — Milestone Payments

$8M—

Other financials

Income statement

Revenue$59.0K-69.3%

Gross profit$963.0K+8,855%

Operating income-$20.9M-42.5%

Net income-$19.6M-49.3%

EPS (diluted)-$0.98+21.6%

Balance sheet

Cash & equivalents$25.3M-79.8%

Total debt$328.0K-59.1%

Total equity$68.3M-44.3%

Total assets$99.9M-27.9%

Cash flow

Operating cash flow-$17.7M-87.1%

CapEx-—

Free cash flow-$15.0M-444%

Valuation

Market cap$946.18M+1,783%

Enterprise value$921.19M-1,342%

P/S1,892.4×+1,852×

Profitability

Gross margin182%+176pp

Operating margin-15,536.1%-17,275pp

Net margin-7,965.8%-10,750pp

FCF margin-11,123.8%-13,374pp

Returns & leverage

Return on equity-88.8%—

Debt / equity0×0.0×

Current ratio7.7×-14.9×

Where this comes from

Reported directly by Avalo Therapeutics in its filing.

Tagged under the XBRL concept avtx:CollaborativeAgreementMilestonePayment.

The official record: Avalo Therapeutics’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about Avalo Therapeutics's avtx-009 — collaborative agreement, milestone payment.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is Avalo Therapeutics's AVTX-009 — collaborative agreement, milestone payment?: Avalo Therapeutics (AVTX) reported AVTX-009 — collaborative agreement, milestone payment of $12.75M in Q2 2026.
What does AVTX-009 — collaborative agreement, milestone payment mean?: This represents revenue or cash inflows recognized upon the achievement of specific clinical, regulatory, or commercial milestones related to the development of a therapeutic asset. It reflects the successful progression of a drug candidate through the development pipeline under a partnership or licensing agreement. Such payments are critical indicators of external validation and the realization of value from collaborative research efforts.